Akums Drugs & Pharmaceuticals Ltd Share Price
As on 18 November 2025 at 23:55 IST
Akums Drugs and Pharmaceuticals Q1 FY26 Results:
Net profit for the period increased 5.5% to ₹63.5 crores in Q1 FY26, from ₹60.2 crores in Q1 FY25. Total income for the quarter increased 2% year-on-year to ₹1,051 crores from ₹1,026 crores.
About Akums Drugs & Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Ltd. was founded in the year 2004. Headquartered in Delhi, India, it has rapidly established itself as a prominent player in the pharmaceutical industry. The company has carved out a niche as a leading Contract Development and Manufacturing Organization (CDMO). Akum’s diverse portfolio allows it to cater to a wide array of healthcare needs and market demands. Its expertise spans various dosage forms, including oral solids, injectables, cosmetics and nutraceuticals. Akums’ success is mainly seen through its commitment to providing customized solutions that meet global standards. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-4.60%
Over 6 Months
-20.25%
Over 1 Year
-20.34%
Over 3 Years
None%
Akums Drugs & Pharmaceuticals Ltd Summary
Close ₹440.50
Open ₹425.85
High ₹445.05
Low ₹424.30
Volume 2,54,419
Net Turnover (in Cr) ₹11.18
52Wk High ₹705.70
52Wk Low ₹405
52Wk High / Low
405
705.70
Akums Drugs & Pharmaceuticals Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹6,933.21
EPS (TTM) 8.71
Book Value (BV) 150.82
Div. Yield -
P/E (TTM) 50.55
Price/Book Value 2.92
Delivery % 31.48 %
Face Value 2
Key Ratios
PE Ratio 45.11
PB Ratio 3.15
EV to Sales 5.46
PEG Ratio -0.24
ROA 6.78
ROE 13.15
Debt-Equity 0.13
Net Profit Margin 12.27
Operating Profit Margin 20.03
Akums Drugs & Pharmaceuticals Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,170.28 | 4,212.21 | 3,744.89 | 3,694.52 | 2,743.79 |
| Total Expenses | 3,841.72 | 4,231.45 | 3,519.89 | 3,874.95 | 2,561.87 |
| Profit Before Tax | 345.25 | -45.28 | 150.30 | -193.20 | 172.26 |
| Profit After Tax | 343.78 | 0.79 | 97.82 | -250.87 | 123.44 |
| Operating Profit After Depreciation | 363.16 | 31.37 | 271.25 | -163.77 | 188.66 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,400.54 | 1,191.05 | 1,097.47 | 1,020.79 | 833.80 |
| Total Non Current Assets | 1,838.83 | 1,575.48 | 1,387.65 | 1,204.98 | 1,034.61 |
| Total Current Assets | 2,274.61 | 1,940.88 | 1,878.87 | 1,864.06 | 1,157.40 |
| Total Assets | 4,113.44 | 3,516.36 | 3,266.53 | 3,069.05 | 2,192.02 |
| Total Shareholder's Fund | 3,047.01 | 709.50 | 717.19 | 621.98 | 884.85 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 465.20 | 498.26 | 176.63 | 31.85 | 134.89 |
| Net Cash Used In Investing Activities | -547.84 | -330.80 | -304.70 | -234.82 | -109.38 |
| Net Cash Used In Financing Activities | 72.79 | -108.02 | 124.54 | 236.04 | -95.22 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,439.84 | 1,538.24 | 1,382.98 | 1,220.54 | 891.95 |
| Total Expenses | 1,232.01 | 1,621.78 | 1,088.13 | 1,555.51 | 837.65 |
| Profit Before Tax | 207.84 | -102.93 | 150.32 | -334.98 | -195.20 |
| Profit After Tax | 161 | -165.45 | 125.43 | -381.77 | -145.43 |
| Operating Profit After Depreciation | 223.15 | -65.23 | 308.03 | -331.32 | 55.11 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 340.54 | 298.57 | 253.27 | 233.50 | 229.09 |
| Total Non Current Assets | 1,851.73 | 1,562.18 | 1,373.12 | 1,258.79 | 916.94 |
| Total Current Assets | 833.18 | 533.24 | 521.08 | 555.16 | 381.41 |
| Total Assets | 2,684.91 | 2,095.43 | 1,894.21 | 1,813.95 | 1,298.35 |
| Total Shareholder's Fund | 2,305.25 | 143.88 | 311.50 | 185.54 | 567.05 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 91 | 247.91 | 94.01 | 228.31 | 55.57 |
| Net Cash Used In Investing Activities | -458.84 | -165.44 | -202.17 | -297.96 | -99.96 |
| Net Cash Used In Financing Activities | 375.38 | -20.74 | 89.90 | 94.99 | 2.60 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,017.53 | 1,024.03 | 1,055.55 | 1,010.41 | 1,033.09 |
| Total Expenses | 923.06 | 895.06 | 961.63 | 889.05 | 911.90 |
| Profit Before Tax | 65.68 | 95.64 | 75.15 | 91.05 | 91.59 |
| Profit After Tax | 42.70 | 64.69 | 149.61 | 66.31 | 66.65 |
| Operating Profit after Depreciation | 126.84 | 155.70 | 111.47 | 135.92 | 134.66 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 309.32 | 332.44 | 328.75 | 337.41 | 328.35 |
| Total Expenses | 292.42 | 288.33 | 311.03 | 303.38 | 285.28 |
| Profit Before Tax | 31.21 | 59.51 | 37.05 | 54.90 | 61.62 |
| Profit After Tax | 23.46 | 44.87 | 27.59 | 41.17 | 50.37 |
| Operating Profit after Depreciation | 43.98 | 72.67 | 49.77 | 67.87 | 75.19 |
Akums Drugs & Pharmaceuticals Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 428.18
S2 415.87
S3 407.43
Pivot 436.62
R1 448.93
R2 457.37
R3 469.68
Moving Average
20 SMA 456.27
50 SMA 457.99
100 SMA 490.82
200 SMA 507.30
Akums Drugs & Pharmaceuticals Ltd Corporate Actions
No available data
Akums Drugs & Pharmaceuticals Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
Akums Drugs & Pharmaceuticals Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Franklin India Opportunities Fund | 1.43% |
| Templeton India Value Fund | 1.22% |
| Tata Children's Fund (After 7 Years) | 1.20% |
| Franklin India Multi Cap Fund | 1.09% |
| Tata India Pharma & Healthcare Fund | 0.89% |
Akums Drugs & Pharmaceuticals Ltd News
Akums Drugs & Pharmaceuticals schedules board meeting
On 13 November 2025
11 Nov 2025, 12:29 pm
Stock Alert: Akums Drugs, GMR Power, Brigade Ent, JNK India, Interarch Building
25 Aug 2025, 08:00 am
Akums Drugs & Pharma signs pact with Zambia Govt to supply medicines
Akums Drugs & Pharmaceuticals said that it has executed a framework agreement with Government of the Republic of Zambia (GRZ) to establish a local manufacturing facility and supply medicines in Zambia.
23 Aug 2025, 02:11 pm
Akums Drugs & Pharmaceuticals to discuss results
On 8 August 2025
04 Aug 2025, 04:38 pm
Akums Drugs & Pharmaceuticals AGM scheduled
On 18 July 2025
29 May 2025, 12:07 pm
Akums Drugs & Pharmaceuticals Ltd Stock Analysis
- Annual revenue for Akums Drugs & Pharmaceuticals Ltd decreased by 6.40% to ₹1,439.84 crore in FY 2025 from ₹1,538.24 crore in FY 2024.
- Annual Net Profit for Akums Drugs & Pharmaceuticals Ltd decreased by 197.31% to ₹161 crore in FY 2025 from ₹-165.45 crore in FY 2024.
- Promoter Shareholding in Akums Drugs & Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 75.26% in June 2025 to 75.26% in September 2025.
- Akums Drugs & Pharmaceuticals Ltd delivered a 1-year return of -20.34% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Akums Drugs & Pharmaceuticals Ltd share price moved down by 1.82% from its previous close of INR ₹440.50. The latest Akums Drugs & Pharmaceuticals Ltd share price is INR ₹432.50.
- Akums Drugs & Pharmaceuticals Ltd share price today has been at a low of 428.70 and a high of 439.80. Over the past 52 weeks, the Akums Drugs & Pharmaceuticals Ltd share price has seen a low of 405 and a high of 705.70.
About Akums Drugs & Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Ltd., founded in 2004 and headquartered in Delhi, India, has rapidly established itself as a prominent player in the pharmaceutical industry. The company has carved out a niche as a leading Contract Development and Manufacturing Organization (CDMO). It offers a comprehensive range of pharmaceutical products and services.
Akums’ main promoter is the Akums Master Trust, which holds 40.79% of its equity. The company’s Managing Directors, Mr. Sanjeev Jain and Mr. Sandeep Jain, own 17.23% and 17.24% stakes, respectively. Under their leadership, Akums has experienced significant growth. It has also built a strong reputation for quality and innovation. Apart from them, there are other managerial promoters who have contributed to the company's success. They are
Akums’ success is underpinned by its commitment to providing customised solutions that meet global standards. The company is renowned for its high-quality, safe, and effective formulations. Its manufacturing facilities and expertise have positioned it as a preferred partner for many in the industry.
It is not explicitly labelled as the top stock in its sector. However, Akums’ rapid growth and market presence reflect its importance in the pharmaceutical manufacturing landscape. The company’s focus on innovation and quality has enabled it to stay competitive in a rapidly evolving industry. As Akums continues to expand its reach, it remains dedicated to its mission of providing quality products and services.
Akums provides a range of services that cover the entire spectrum of pharmaceutical manufacturing. These services include formulation development, stability studies, regulatory approvals, packaging, and market launch. By offering such a broad array of services, Akums ensures that their clients can rely on them for all their manufacturing needs. This integrated approach simplifies the process for clients. It also ensures consistency and quality across all stages of production.
One of the key factors behind Akums’ success is its state-of-the-art manufacturing facilities. They operate over 15 advanced manufacturing units that are equipped with the latest technology. These facilities are capable of producing a wide range of dosage forms. This includes tablets, capsules, liquid orals, injectables, and more. The company’s commitment to maintaining high standards is evident in its numerous certifications, including WHO-GMP, ISO 9001, and ISO 14001.
Innovation is at the heart of Akums’ operations. The company invests heavily in research and development to stay ahead of industry trends. This focus on innovation has led to the development of new drug formulations and delivery systems. For instance, Akums recently received approval from the Drug Controller General of India (DCGI) to launch an antidiabetic drug called Lobeglitazone. This drug offers several advantages, including a higher safety profile. It also offers greater effectiveness at lower dosages.
Akums has also formed strategic partnerships with various companies. This is to expand their capabilities and market reach. In 2019, they received a significant investment from Quadria Capital, a healthcare-focused private equity firm. This partnership has enabled Akums to further enhance their manufacturing capabilities. It has also helped the company explore new growth opportunities. Additionally, Akums has collaborated with several multinational companies. This is to manufacture a diverse range of products, including pharmaceuticals, cosmetics, and more.
Sustainability is another area where Akums is making a difference. The company is committed to reducing its environmental footprint through various initiatives. These include the use of renewable energy sources and water conservation efforts. As a result, Akums contribute to environmental protection. It also ensures long-term operational efficiency and cost savings.
Looking ahead, Akums aims to continue its growth trajectory by expanding its market share and revenue. The company plans to increase its revenue to around ₹10,000 crore and capture a 20% market share in the next few years. To achieve these goals, Akums will focus on enhancing its service offerings and leveraging its partnerships. The company also plans to venture into new areas, such as biosimilars and vaccines, which present significant growth opportunities.
Overall, Akums Drugs and Pharmaceuticals Ltd. is revolutionising contract manufacturing in the pharmaceutical industry. The company achieves this through its comprehensive service offerings and quality. As the company continues to grow, it is well-positioned to meet the changing needs of the pharmaceutical industry. It is also ready to contribute to the development of safe and effective medications for patients worldwide.
Akums’ main promoter is the Akums Master Trust, which holds 40.79% of its equity. The company’s Managing Directors, Mr. Sanjeev Jain and Mr. Sandeep Jain, own 17.23% and 17.24% stakes, respectively. Under their leadership, Akums has experienced significant growth. It has also built a strong reputation for quality and innovation. Apart from them, there are other managerial promoters who have contributed to the company's success. They are
- Sanjay Sinha
- Matangi Gowrishankar
- Nand Lal Kalra
- Sunil Kumar Thakur
- Kewal Kundanlal Handa
- Satwinder Singh
Akums’ success is underpinned by its commitment to providing customised solutions that meet global standards. The company is renowned for its high-quality, safe, and effective formulations. Its manufacturing facilities and expertise have positioned it as a preferred partner for many in the industry.
It is not explicitly labelled as the top stock in its sector. However, Akums’ rapid growth and market presence reflect its importance in the pharmaceutical manufacturing landscape. The company’s focus on innovation and quality has enabled it to stay competitive in a rapidly evolving industry. As Akums continues to expand its reach, it remains dedicated to its mission of providing quality products and services.
How Akums is Revolutionising Contract Manufacturing in Pharma
Akums Drugs and Pharmaceuticals Ltd. is making major strides in the pharmaceutical industry. Founded in 2004 by the Jain brothers, Akums has grown to become India’s largest contract research and manufacturing services (CRAMS) company. This growth is driven by their commitment to quality and innovation.Akums provides a range of services that cover the entire spectrum of pharmaceutical manufacturing. These services include formulation development, stability studies, regulatory approvals, packaging, and market launch. By offering such a broad array of services, Akums ensures that their clients can rely on them for all their manufacturing needs. This integrated approach simplifies the process for clients. It also ensures consistency and quality across all stages of production.
One of the key factors behind Akums’ success is its state-of-the-art manufacturing facilities. They operate over 15 advanced manufacturing units that are equipped with the latest technology. These facilities are capable of producing a wide range of dosage forms. This includes tablets, capsules, liquid orals, injectables, and more. The company’s commitment to maintaining high standards is evident in its numerous certifications, including WHO-GMP, ISO 9001, and ISO 14001.
Innovation is at the heart of Akums’ operations. The company invests heavily in research and development to stay ahead of industry trends. This focus on innovation has led to the development of new drug formulations and delivery systems. For instance, Akums recently received approval from the Drug Controller General of India (DCGI) to launch an antidiabetic drug called Lobeglitazone. This drug offers several advantages, including a higher safety profile. It also offers greater effectiveness at lower dosages.
Akums has also formed strategic partnerships with various companies. This is to expand their capabilities and market reach. In 2019, they received a significant investment from Quadria Capital, a healthcare-focused private equity firm. This partnership has enabled Akums to further enhance their manufacturing capabilities. It has also helped the company explore new growth opportunities. Additionally, Akums has collaborated with several multinational companies. This is to manufacture a diverse range of products, including pharmaceuticals, cosmetics, and more.
Sustainability is another area where Akums is making a difference. The company is committed to reducing its environmental footprint through various initiatives. These include the use of renewable energy sources and water conservation efforts. As a result, Akums contribute to environmental protection. It also ensures long-term operational efficiency and cost savings.
Looking ahead, Akums aims to continue its growth trajectory by expanding its market share and revenue. The company plans to increase its revenue to around ₹10,000 crore and capture a 20% market share in the next few years. To achieve these goals, Akums will focus on enhancing its service offerings and leveraging its partnerships. The company also plans to venture into new areas, such as biosimilars and vaccines, which present significant growth opportunities.
Overall, Akums Drugs and Pharmaceuticals Ltd. is revolutionising contract manufacturing in the pharmaceutical industry. The company achieves this through its comprehensive service offerings and quality. As the company continues to grow, it is well-positioned to meet the changing needs of the pharmaceutical industry. It is also ready to contribute to the development of safe and effective medications for patients worldwide.
FAQ’s
What is the share price of Akums Drugs & Pharmaceuticals Ltd today?
Akums Drugs & Pharmaceuticals Ltd share price as on 18 Nov 2025 is ₹ 432.5
What is the Market Cap of Akums Drugs & Pharmaceuticals Ltd?
The market cap of Akums Drugs & Pharmaceuticals Ltd stock is ₹6,933.21 Cr.
What is the PE Ratio of Akums Drugs & Pharmaceuticals Ltd?
The Price to Earnings (P/E) Ratio of Akums Drugs & Pharmaceuticals Ltd is 45.11
What is the PB Ratio of Akums Drugs & Pharmaceuticals Ltd?
The Price to Book (P/B) Ratio of Akums Drugs & Pharmaceuticals Ltd is 3.15
What is the 52 week high of Akums Drugs & Pharmaceuticals Ltd Share Price?
The 52 week high of Akums Drugs & Pharmaceuticals Ltd share price stands at ₹705.70
What is the 52 week low of Akums Drugs & Pharmaceuticals Ltd Share Price?
The 52 week low of Akums Drugs & Pharmaceuticals Ltd share price stands at ₹405
How can I buy shares of Akums Drugs & Pharmaceuticals Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Akums Drugs & Pharmaceuticals Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
